Which pharmaceutical products are exempted from Section 232 tariffs?

Nine product categories receive exemptions: orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell therapy products, gene therapy products, antibody drug conjugates, medical countermeasures for chemical/biological/radiological/nuclear threats, and animal health drugs. Additionally, unpatented animal health products now qualify as generic pharmaceutical articles eligible for exemption consideration.

What countries currently qualify for the zero-tariff rate?

As of the notice, 20 jurisdictions with current or forthcoming trade and security framework agreements qualify: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom, and Vietnam. BIS may update this list in future notices.

Can products from non-qualifying countries still avoid tariffs?

Yes, products that meet an urgent U.S. health need can qualify for zero-tariff treatment regardless of jurisdiction. BIS established a submission and approval process for companies to request exemptions based on urgent health need criteria.

What operational changes should supply chain teams make?

Pharma import teams should: audit current supplier locations against the eligible jurisdiction list, prioritize sourcing from qualified countries, evaluate whether their products fit the nine exempted categories, and document compliance with finished product definitions. For products not in qualifying jurisdictions, assess whether urgent health need status is defensible for tariff appeals.

How does this guidance affect active pharmaceutical ingredient (API) imports?

The notice clarifies that 'pharmaceutical articles' encompasses finished products, active pharmaceutical ingredients, and key starting materials. This means APIs and precursor materials may also qualify for exemptions if they derive from eligible jurisdictions and meet product category requirements, creating supply chain flexibility for API sourcing.

Trade Policy & Tariffs

High Impact

BIS Defines Pharma Products Exempt from Section 232 Tariffs

Nov 4, 2026

Get tomorrow's supply chain signal

Daily supply-chain brief. Free, unsubscribe anytime.

The signal

The Bureau of Industry and Security has issued critical guidance defining which pharmaceutical products qualify for zero-tariff treatment under Section 232, addressing Presidential Proclamation 11020 that imposes 10-100 percent tariffs on imported patented drugs and their ingredients. The exemptions cover nine product categories: orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell therapy products, gene therapy products, antibody drug conjugates, medical countermeasures, and animal health drugs.

To qualify, products must originate from jurisdictions with trade and security framework agreements or address urgent U.S. health needs. This guidance is material for pharmaceutical supply chain teams because it directly impacts import costs, sourcing strategy, and supplier selection across multiple therapeutic modalities.

For companies importing from the 20 currently eligible jurisdictions, the zero-tariff pathway creates immediate cost-saving opportunities and operational advantages over competitors sourcing from non-qualified countries.

#section-232-tariffs

#pharmaceutical-tariffs

#trade-policy

#tariff-exemptions

#biotech-imports

#supply-chain-tariffs

Frequently Asked Questions

What This Means for Your Supply Chain

Simulation Suggestion

this month

What if your primary API supplier is in a non-qualifying country?

Simulate the impact of needing to either relocate API sourcing to a qualified jurisdiction, absorb 10-100 percent tariff costs, or pursue an urgent health need exemption. Model increased lead times due to supplier qualification, cost increases, and potential inventory buffering requirements.

Run this scenario

Simulation Suggestion

strategic

What if you transition to a gene therapy or cell therapy product line?

Simulate the competitive advantage of entering emerging therapeutic categories with automatic zero-tariff eligibility from qualified jurisdictions. Model cost savings against R&D and manufacturing investment, and compare service levels vs. competitors in traditional pharma categories facing full tariffs.

Run this scenario

Simulation Suggestion

strategic

What if a new eligible jurisdiction is added to the framework agreement list?

Simulate the sourcing flexibility gained by an additional qualified country entering the trade and security framework. Model cost reductions, geographic diversification benefits, lead time changes, and inventory optimization opportunities as new supplier capacity becomes available at zero-tariff rates.

Run this scenario

Go deeper:

Digital Twin in Supply Chain: What It Is and How to Choose Software

What a supply chain digital twin is, how to evaluate twin software, what it costs and how long it takes, and how it differs from network design tools.

Trade Policy & TariffsHigh Impact

Trump Updates Canadian Tariff List: 22 Products Removed, 100 Added

Nov 4, 2026

Trade Policy & TariffsHigh Impact

Section 301 China Tariffs Officially Extended, USTR Signals Review Ahead

Nov 2, 2026

Trade Policy & TariffsHigh Impact

Section 338 Tariffs on Canadian Goods Challenged in Court

Nov 4, 2026

Get the daily supply chain briefing

Top stories, Pulse score, and disruption alerts. No spam. Unsubscribe anytime.